This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Refuting Star Scientific's Refutation

In my opinion, Star is peddling modern-day snake oil, but the company isn't stupid. Its marketing department and the stock promoters who tout Star cleverly link anatabine, a compound found in nicotine, to real medical research investigating the role of nicotinic receptors in the brain.

What Star and its promoters neglect to mention, however, is that medicinal chemists spend considerable time and brainpower creating drugs potent enough to activate nicotinic receptors. This is work done by actual drug companies -- Pfizer (PFE), Targacept (TRGT), Envivo Pharmaceuticals, Novartis (NVS). So far, the research has led to more failures and setbacks than medical breakthroughs.

The notion that Star Scientific has cracked the code with a nutritional supplement like anatabine is ludicrous. It also explains why Star talks more today about anatabine's alleged effect on inflammation and NF-KB inhibition. Piggybacking on a disappointing line of real medical research doesn't help generate anatabine sales at the local GNC store. Actually, nothing Star does helps the top line, judging by the $4.5 million in revenue and an operating loss of $19.8 million posted by the company through three quarters of 2012. Meantime, Star Scientific's market cap exceeds $300 million.

Talk about false and misleading...

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
STSI $0.21 3.14%
AAPL $118.03 -0.71%
FB $105.52 -0.21%
GOOG $748.15 -0.02%
TSLA $229.64 5.22%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs